I had an informative interview with Matthew Stork, the newly appointed chief executive of Aim-traded Cambridge Cognition (COG:67p), a small-cap company that has developed a suite of computer-based cognitive assessments to improve the understanding, diagnosis and treatment of neurological and psychological diseases.
Mr Stork joined the company three months ago as chief operating officer with the mandate to play a key role in driving penetration of cognitive and clinical assessment markets and forming strong relationships with corporate partners. In late April, he replaced Dr Steven Powell as chief executive when Dr Powell became chairman. It’s an interesting appointment as Mr Stork has expertise in a broad range of relevant sectors including healthcare IT, diagnostic imaging, clinical service delivery, capital devices and pharmaceuticals. He previously held executive roles at General Electric, Toshiba Medical and Smith & Nephew.
It’s timely, too, given that Cambridge Cognition raised £2.3m net of expense in a placing, at 72p a share, in early March this year, primarily to accelerate sales growth overseas and investment in: